| Index | — | P/E | 34.59 | EPS (ttm) | 2.32 | Insider Own | 1.95% | Shs Outstand | 47.55M | Perf Week | 3.65% |
| Market Cap | 3.82B | Forward P/E | 30.52 | EPS next Y | 2.63 | Insider Trans | -2.18% | Shs Float | 46.92M | Perf Month | 14.82% |
| Enterprise Value | 3.78B | PEG | 3.17 | EPS next Q | — | Short Float | 6.12% | Perf Quarter | 17.56% | ||
| Income | 115.00M | P/S | 5.79 | EPS this Y | 12.22% | Short Ratio | 5.57 | Perf Half Y | 22.95% | ||
| Sales | 659.00M | P/B | 12.39 | EPS next Y | 14.04% | ROA | 16.54% | Short Interest | 2.87M | Perf YTD | 15.55% |
| Book/sh | 6.48 | P/C | 33.18 | EPS next 5Y | 11.37% | ROE | 34.61% | 52W High | 83.18 -3.51% | Perf Year | 22.70% |
| Cash/sh | 2.42 | P/FCF | 35.01 | EPS past 3/5Y | 1.84% 5.96% | ROIC | 19.41% | 52W Low | 51.91 54.61% | Perf 3Y | -3.30% |
| Dividend Est. | 1.24 (1.54%) | EV/EBITDA | 23.75 | Sales past 3/5Y | 4.30% 7.79% | Gross Margin | 25.50% | Volatility | 2.64% 2.56% | Perf 5Y | -29.32% |
| Dividend TTM | 1.23 (1.53%) | EV/Sales | 5.73 | EPS Y/Y TTM | 13.17% | Oper. Margin | 21.31% | ATR (14) | 2.13 | Perf 10Y | 194.32% |
| Dividend Ex-Date | Dec 04, 2026 | Quick Ratio | 1.94 | Sales Y/Y TTM | 15.21% | Profit Margin | 17.40% | RSI (14) | 78.37 | Recom | 2.25 |
| Dividend Gr. 3/5Y | 7.72% 9.57% | Current Ratio | 1.94 | EPS Q/Q | 16.36% | SMA20 | 9.50% | Beta | 0.66 | Target Price | 72.00 |
| Payout | 53.46% | Debt/Eq | 0.24 | Sales Q/Q | 18.37% | SMA50 | 14.34% | Rel Volume | 1.53 | Prev Close | 78.31 |
| Employees | 1,012 | LT Debt/Eq | 0.24 | Earnings | Oct 29 | SMA200 | 20.58% | Avg Volume | 504.86K | Price | 80.26 |
| IPO Date | Aug 17, 1990 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.37% 16.10% | Net Debt/EBITDA | -0.25 | Volume | 772,751 | Change | 2.49% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Reiterated | UBS | Neutral | $75 → $72 |
| Jun-02-26 | Reiterated | UBS | Neutral | $85 → $75 |
| Feb-09-26 | Reiterated | UBS | Neutral | $81 → $85 |
| Dec-15-25 | Reiterated | UBS | Neutral | $88 → $81 |
| Nov-17-25 | Upgrade | William Blair | Market Perform → Outperform | |
| Jul-26-24 | Reiterated | Truist Securities | Buy | $120 |
| Jun-26-24 | Reiterated | UBS | Neutral | $88 |
| May-13-20 | Upgrade | Sidoti & Co. | Neutral → Buy | |
| Mar-19-20 | Upgrade | Sidoti & Co. | Neutral → Buy | |
| Jan-26-18 | Upgrade | SunTrust Robinson Humphrey | Hold → Buy |
Exponent, Inc. functions as a global leader in scientific and engineering consulting, operating through its subsidiaries. The firm's activities are divided into two principal segments: Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific division offers a broad spectrum of services encompassing biomechanics, biomedical sciences, structural analysis, civil engineering, construction advisory, data analytics, electrical and computer science, human factors, materials and corrosion science, mechanical engineering, polymer chemistry, thermal dynamics, and vehicle system engineering. Concurrently, the Environmental and Health segment specializes in areas such as chemical regulatory compliance, food safety, ecological and biological studies, earth and environmental sciences, and various health-related scientific fields. With expertise spanning approximately 90 technical disciplines, Exponent is dedicated to addressing complex and pressing issues for its stakeholders. Its client base is diverse, covering industries like chemicals, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, heavy industrial equipment, and transportation. The company, originally established in 1967 as The Failure Group, Inc., rebranded as Exponent, Inc. in 1998, and its headquarters are located in Menlo Park, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 1/2/2026 | FY 2024 1/3/2025 | FY 2023 12/29/2023 | FY 2022 12/30/2022 | FY 2021 12/31/2021 | FY 2020 1/1/2021 | FY 2019 1/3/2020 | FY 2018 12/28/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 659 | 582 | 559 | 537 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 492 | 437 | 416 | 401 | — | — | — | — | — | |
| Gross Profit | 168 | 145 | 142 | 136 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 27 | 26 | 23 | 24 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 140 | 120 | 120 | 111 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 20 | 28 | 28 | 25 | — | — | — | — | — | |
| Net Income Before Taxes | 160 | 147 | 147 | 136 | — | — | — | — | — | |
| Income Taxes | 45 | 41 | 38 | 36 | — | — | — | — | — | |
| Consolidated Net Income | 115 | 106 | 109 | 100 | — | — | — | — | — | |
| Net Income From Continuing Operations | 115 | 106 | 109 | 100 | — | — | — | — | — | |
| Net Income | 115 | 106 | 109 | 100 | — | — | — | — | — | |
| EPS (Recurring) | 2.32 | 2.08 | 2.13 | 1.96 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.32 | 2.08 | 2.13 | 1.96 | — | — | — | — | — | |
| EPS (Diluted) | 2.32 | 2.07 | 2.11 | 1.94 | — | — | — | — | — | |
| EBITDA | 159 | 157 | 157 | 145 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 34.59 | 33.89 | 42.14 | 45.38 | — | — | — | — | — | |
| Price To Sales Ratio | 5.85 | 6.15 | 8.11 | 8.36 | — | — | — | — | — | |
| Gross Margin | 25.49 | 24.91 | 25.40 | 25.33 | — | — | — | — | — | |
| Operating Margin | 21.24 | 20.62 | 21.47 | 20.67 | — | — | — | — | — | |
| Net Margin | 17.45 | 18.21 | 19.50 | 18.62 | — | — | — | — | — | |
| Shares Outstanding | 48 | 51 | 51 | 51 | — | — | — | — | — | |
| Market Capitalization | 3,852 | 3,578 | 4,534 | 4,490 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Souri Shukri Jeries | Group Vice President | Sep 18 '26 | Buy | 68.45 | 184 | 12,594 | 40,873 | Sep 22 |
| Corrigan Catherine | Chief Executive Officer | Aug 17 '26 | Option Exercise | 29.05 | 2,379 | 69,110 | 130,815 | Aug 18 |
| Corrigan Catherine | Chief Executive Officer | Aug 17 '26 | Sale | 66.28 | 1,707 | 113,136 | 129,108 | Aug 18 |
| Corrigan Catherine | Chief Executive Officer | Jul 28 '26 | Option Exercise | 37.45 | 12,665 | 474,304 | 128,436 | Jul 30 |
| Corrigan Catherine | Chief Executive Officer | Jul 15 '26 | Sale | 62.78 | 1,737 | 109,045 | 115,771 | Jul 17 |
| Corrigan Catherine | Chief Executive Officer | Jul 15 '26 | Option Exercise | 29.05 | 2,379 | 69,110 | 117,508 | Jul 17 |
| Corrigan Catherine | Chief Executive Officer | Jun 25 '26 | Option Exercise | 25.41 | 7,872 | 199,988 | 115,129 | Jun 29 |
| Corrigan Catherine | President & CEO | Jun 15 '26 | Option Exercise | 26.95 | 5,605 | 151,070 | 109,050 | Jun 17 |
| Corrigan Catherine | President & CEO | Jun 15 '26 | Sale | 57.13 | 4,119 | 235,303 | 106,670 | Jun 17 |
| JOHNSTON PAUL R | Director | Jun 03 '26 | Option Exercise | 0.00 | 2,009 | 0 | 62,940 | Jun 04 |
| Lindstrom Carol | Director | Jun 03 '26 | Option Exercise | 0.00 | 2,009 | 0 | 9,405 | Jun 04 |
| Brown George H. | Director | Jun 03 '26 | Option Exercise | 0.00 | 2,009 | 0 | 10,730 | Jun 04 |
| RICHARDSON KAREN A | Director | Jun 03 '26 | Option Exercise | 0.00 | 2,009 | 0 | 2,009 | Jun 04 |
| Zumwalt Debra | Director | Jun 03 '26 | Option Exercise | 0.00 | 2,009 | 0 | 31,830 | Jun 04 |
| James Bradley A | Group Vice President | May 26 '26 | Sale | 57.47 | 2,000 | 114,930 | 1,105 | May 27 |